未登录

D

Daniel J. Bratton

GlaxoSmithKline

H指数:24

被引数:4,547

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Selection of Quantitative Decision-Making Criteria Using Weighted Decision Error Rates

基于加权决策错误率的定量决策标准选择

Pharmaceutical Statistics

IF1.4

2026-01-010

PRE

Facilities for optimizing and designing multiarm multistage (MAMS) randomized controlled trials with binary outcomes

优化和设计具有二元结果的多臂多阶段 (MAMS) 随机对照试验的设施

IF2.4

2023-09-221

OA

Comment on: Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma [Respir Med 2020]

评论: dupilumab与其他生物制剂在未控制持续性哮喘患者中的配对间接治疗比较 [Respir Med 2020]

RESPIRATORY MEDICINE

IF3.1

2022-01-010

OAAI

BENEFIT-RISK PROFILES OF FLUTICASONE FUROATE/UMECLIDINIUM/VILANTEROL (FF/UMEC/VI) VS UMEC/VI IN PATIENTS WITH COPD: A MARKOV MODEL

IF8.6

2020-10-010

OAAI

Severe eosinophilic asthma with nasal polyposis: A phenotype for improved sinonasal and asthma outcomes with mepolizumab therapy

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

IF11.2

2020-06-0144

OAAI

Durability of mepolizumab treatment response between doses

EUROPEAN RESPIRATORY JOURNAL

IF21

2019-11-210

PRE

Baseline blood eosinophil count as a predictor of treatment response to the licensed dose of mepolizumab in severe eosinophilic asthma

RESPIRATORY MEDICINE

IF3.1

2019-11-0147

OAAI

Update: Mepolizumab treatment in patients with severe eosinophilic asthma and prior omalizumab use

更新: 美泊利单抗治疗严重嗜酸性粒细胞性哮喘和先前使用奥马珠单抗的患者

IF12

2019-10-0212

OAAI

Effect of mepolizumab in severe eosinophilic asthma according to omalizumab eligibility

RESPIRATORY MEDICINE

IF3.1

2019-07-0132

OAAI

Indirect treatment comparison of asthma biologics fraught with methodology issues Reply

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

IF11.2

2019-03-010

PREAI

Efficacy Of 100 Mg SC Mepolizumab For Severe Eosinophilic Asthma (SEA) Across Body Weight: Meta-Analysis

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

IF11.2

2019-02-010

OAAI

Efficacy Of 100 Mg SC Mepolizumab For Severe Eosinophilic Asthma (SEA) Across Blood Eosinophil Counts: Meta-Analysis

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

IF11.2

2019-02-011

OAAI

Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

IF11.2

2019-01-01173

OAAI

Eosinophils as a predictor of mepolizumab treatment responses in COPD

EUROPEAN RESPIRATORY JOURNAL

IF21

2018-11-190

PRE

Mepolizumab improves activity limitation in severe eosinophilic asthma

EUROPEAN RESPIRATORY JOURNAL

IF21

2017-12-060

PRE

Improvement in rhinosinusitis health related quality of life in patients with severe eosinophilic asthma

EUROPEAN RESPIRATORY JOURNAL

IF21

2017-12-065

PRE

Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial

LANCET RESPIRATORY MEDICINE

IF32.8

2017-05-01435

PREAI

Risk of Sleepiness-Related Accidents in Switzerland: Results of an Online Sleep Apnea Risk Questionnaire and Awareness Campaigns

FRONTIERS IN MEDICINE

IF3

2017-04-124

OAAI

Effects of CPAP and Mandibular Advancement Devices on Health-Related Quality of Life in OSA A Systematic Review and Meta-analysis

IF8.6

2017-04-0187

PREAI

Efficacy Of Mepolizumab In Patients With Severe Eosinophilic Asthma And Nasal Polyps

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

IF11.2

2017-02-015

OAAI